HSBC raised the firm’s price target on AstraZeneca (AZN) to $108 from $95 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca price target raised to $105 from $95 at TD Cowen
- AstraZeneca, Daiichi Sankyo dose first patient in DESTINY-Ovarian01 trial
- AstraZeneca price target raised to 16,000 GBp from 14,000 GBp at JPMorgan
- JPMorgan ups AstraZeneca target, adds to Analyst Focus List
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’